Also of concern is the auditor's review final comment:
Without modifying our conclusion, we draw attention to Note 1 in the half-year financial report, which indicates that the ability of the consolidated entity to continue as a going concern is dependent upon the future successful raising of necessary funding through equity, and/or sale of non-core assets. These conditions, along with other matters as set out in Note 1, indicate the existence of a material uncertainty that may cast significant doubt about the consolidated entity’s ability to continue as a going concern and therefore, the consolidated entity may be unable to realise its assets and discharge its liabilities in the normal course of business.
- Forums
- ASX - By Stock
- AVR
- good bad or indifferent
good bad or indifferent, page-62
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$17.80 |
Change
-0.200(1.11%) |
Mkt cap ! $341.1M |
Open | High | Low | Value | Volume |
$18.00 | $18.00 | $17.75 | $46.16K | 2.581K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 122 | $17.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.91 | 32 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 122 | 17.800 |
1 | 26 | 17.740 |
1 | 443 | 17.700 |
1 | 26 | 17.650 |
1 | 200 | 17.560 |
Price($) | Vol. | No. |
---|---|---|
17.910 | 32 | 2 |
17.930 | 46 | 2 |
17.950 | 271 | 3 |
18.000 | 518 | 2 |
18.190 | 26 | 2 |
Last trade - 13.54pm 15/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online